Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 1,694 trials

Early Stage Arthritis: Baricitinib Study

We are studying the effects of baricitinib on joint inflammation in people with early stage arthritis. The trial will also look at safety and potential indicators of disease progression.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Standard MedicinesRheumatology

Colorectal Cancer: New Treatment with 5-Fluorouracil, Panitumumab, and Sotorasib

We are studying a combination of medications for patients with advanced colorectal cancer who cannot receive standard chemotherapy. The goal is to see if this treatment helps control the disease and improves quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

Type 1 DiabetesEfficacy phase (II)16-20 visitsInvestigational MedicinesEndocrinologyInternal Medicine

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Tacrolimus and Blood Sugar Control in Dialysis Patients

We are studying how tacrolimus affects blood sugar levels in patients on hemodialysis waiting for a kidney transplant. This research may help improve diabetes management in these patients.

Hemodialysis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyNephrology

Chronic Lymphocytic Leukemia: Lisaftoclax and Acalabrutinib Study

We are testing a new drug combination for patients newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The study aims to see if this combination improves survival without disease progression compared to standard treatments.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Extra-Mammary Paget's Disease: PAGETEX Device Study

We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.

Paget's Disease of the Vulva6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Caffeine Treatment for Early Alzheimer's Disease

We are studying whether a 30-week caffeine treatment can help improve thinking and memory in people with early to moderate Alzheimer's disease. This trial compares the effects of caffeine to a placebo to see if it makes a difference.

Alzheimer's Disease6-12 monthsConfirmation phase (III)Investigational MedicinesPartially RemoteNeurology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Diabetes and Bone Health: Alendronate Study

We are investigating how the medication Alendronate impacts bone and blood sugar markers in individuals with type 1 and type 2 diabetes. This study aims to compare the effects between the two types of diabetes and different assessment methods.

Diabetes and Bone Health IssuesMonitoring phase (IV)Standard MedicinesDiabetologyEndocrinologyRheumatology